-
Caveolin-1 Modulates Cholesterol Homeostasis in MASLD Progre
2026-06-04
This study elucidates how Caveolin-1 protects against the progression of metabolic dysfunction-associated steatotic liver disease (MASLD) by restoring cholesterol balance, thereby reducing ER stress and pyroptosis. The findings highlight the mechanistic link between cholesterol accumulation, cellular stress pathways, and liver disease severity, offering new molecular insight for targeted interventions.
-
CCR7–Notch1 Crosstalk Maintains Stemness in Mammary Cancer C
2026-06-04
Boyle et al. (2017) reveal direct signaling interplay between the CCR7 chemokine receptor and Notch1 pathway that sustains stem-like characteristics in MMTV-PyMT mammary cancer cells. This mechanistic insight highlights the importance of dual-pathway targeting to disrupt cancer stem cell-driven recurrence in breast cancer.
-
Resveratrol Disrupts CAF-Driven Breast Cancer Organoid Growt
2026-06-03
This study demonstrates that resveratrol inhibits breast cancer organoid proliferation even in the presence of cancer-associated fibroblasts (CAFs), which are known to promote drug resistance. By integrating a patient-derived organoid-CAF co-culture model and quantifying cell proliferation using EdU assays, the research clarifies the mechanism by which resveratrol suppresses tumor-supportive versican (VCAN) expression in CAFs.
-
SHC-1 Inhibition Modulates CFTR Surface Abundance in Epithel
2026-06-03
This study delineates conserved and cell-type-specific mechanisms by which SHC-1 inhibition increases plasma membrane abundance of the CFTR chloride channel in epithelial cell models. The findings clarify regulatory pathways underlying CFTR trafficking with implications for cystic fibrosis and secretory disease research.
-
Luminescent ATP Cell Viability Assay Kit I in Ferroptosis Wo
2026-06-02
The Luminescent ATP Cell Viability Assay Kit I empowers researchers to dissect regulated cell death, especially ferroptosis, with unmatched sensitivity and workflow speed. Its robust luciferase luminescence detection accelerates drug screening and mechanistic studies, outperforming traditional viability assays.
-
Puromycin Aminonucleoside: Transforming Podocyte Injury Mode
2026-06-02
This article explores the mechanistic foundations and translational impact of puromycin aminonucleoside as a gold-standard tool for modeling podocyte injury and nephrotic syndrome. We examine its role in glomerular lesion induction, workflow optimization, and benchmarking in FSGS research, while providing actionable guidance for translational researchers aiming to bridge preclinical insights with clinical relevance.
-
U 46619: Precision Platelet Aggregation & Vascular Research
2026-06-01
U 46619 (11,9 epoxymethano-prostaglandin H2) is a gold-standard TP receptor agonist that enables high-fidelity modeling of platelet function, vascular tone, and renal responses in experimental settings. Its reproducible potency and robust solubility empower workflows from mechanistic in vitro assays to in vivo hypertension studies.
-
Nigericin Sodium Salt: Technical Guidance for Ion Transport
2026-06-01
Nigericin sodium salt is a potassium ionophore used to modulate ion gradients and cytoplasmic pH in in vitro research workflows, including studies on ion transport across biological membranes and platelet aggregation modulation. It is not intended for diagnostic or clinical applications and requires careful attention to solubility and handling for reliable results.
-
ALT Cancer Cell Sensitivity to ATR Inhibition: Evidence Revi
2026-05-31
This article examines the findings of Deeg et al., who rigorously tested whether cancer cells utilizing alternative lengthening of telomeres (ALT) are broadly hypersensitive to ATR inhibition. Contrary to previous expectations, their results demonstrate that ALT status alone does not confer general hypersensitivity to ATR inhibitors, guiding researchers toward more nuanced interpretations of cell viability in cancer models.
-
Nigericin Sodium Salt: Applied Protocols for Ion Transport R
2026-05-30
Nigericin sodium salt, a potent potassium ionophore, empowers researchers to dissect ion transport, cytoplasmic pH regulation, and platelet aggregation with precision. This guide details optimized workflows, troubleshooting insights, and unique cross-domain advantages—driven by recent advances in in vitro evaluation and supported by APExBIO’s high-purity reagent.
-
Phosphatase Inhibitor Cocktail 1: Precision in Phosphoproteo
2026-05-29
Phosphatase Inhibitor Cocktail 1 (100X in DMSO) empowers researchers to preserve labile phosphorylation states even in challenging sample types, ensuring high-fidelity results in phosphoproteomic and signaling studies. Its robust inhibition profile and workflow versatility set a new standard for reproducibility and signal integrity in Western blotting, co-IP, and advanced multiomics experiments.
-
Dasatinib Monohydrate: Advanced Workflows in CML Research
2026-05-29
Dasatinib Monohydrate (BMS-354825) is a multitargeted tyrosine kinase inhibitor that enables precise modeling of imatinib-resistant chronic myeloid leukemia (CML) and Philadelphia chromosome-positive leukemias. Its unique inhibition profile and proven in vitro, in vivo, and translational utility offer researchers a reliable platform for dissecting kinase signaling and overcoming drug resistance.
-
ECL Western Blotting Substrate: Practical Guide & QC Paramet
2026-05-28
ECL Western Blotting Substrate (SKU K2187) addresses the need for a sensitive, nonradioactive HRP detection reagent in chemiluminescent Western blot assays. It is optimal for protein analysis workflows in molecular biology, cancer biology, and signal transduction research, but should not be used for fluorescent or radioisotopic detection.
-
PPT (Propyl Pyrazole Triol) in ERα Signaling: Protocols & Pr
2026-05-28
PPT (Propyl Pyrazole Triol) stands out as the definitive tool for dissecting estrogen receptor alpha signaling, delivering unmatched selectivity and reproducibility in both cell-based and in vivo assays. This article translates recent biomarker-driven insights and the latest experimental workflows into actionable guidance for maximizing ERα pathway interrogation in oncology and hormone research.
-
ETS1 Modulates SUMOylation-Dependent Mitophagy in BPD Models
2026-05-27
This study reveals how ETS1 orchestrates the SENP2/HSPA8/FUNDC1 axis to inhibit mitochondrial damage-induced autophagy, thereby ameliorating bronchopulmonary dysplasia (BPD) in preclinical models. The findings detail a novel regulatory mechanism linking SUMO1 modification to mitophagy, with implications for targeted intervention in neonatal lung disease.